2024
The role of surgery and deescalation for HPV‐related oropharyngeal cancer
Contrera K, Patel M, Burtness B, Mehra R, Ferris R. The role of surgery and deescalation for HPV‐related oropharyngeal cancer. Cancer 2024 PMID: 38497569, DOI: 10.1002/cncr.35287.Peer-Reviewed Original Research
2023
Top advances of the year: Head and neck cancer
Verma A, Burtness B. Top advances of the year: Head and neck cancer. Cancer 2023, 129: 1308-1312. PMID: 36692372, DOI: 10.1002/cncr.34654.Peer-Reviewed Original ResearchConceptsProgression-free survivalFavorable-risk patientsRisk patientsNeck cancerHuman papillomavirus-associated oropharyngeal cancerGemcitabine/cisplatin chemotherapyImmature survival dataVirus-related cancersIntermediate-risk patientsFirst-line treatmentPhase 3 trialCooperative group trialsTreatment deintensificationMetastatic headOverall survivalPostoperative therapySmoking historyOropharyngeal cancerAntibody nivolumabCisplatin chemotherapyTransoral resectionTransoral surgeryNasopharyngeal cancerGroup trialsGy radiation
2022
Reduced Aspiration Rates for 50 Gy Postoperative Radiation in HPV-Associated Oropharynx Cancer in E3311: A Trial of the ECOG-ACRIN Cancer Research Group
Hutcheson K, Peterson C, Barbon C, Quon H, Mehra R, Ringash J, Lewin J, Flamand Y, Duvvuri U, Ozer E, Thomas G, Kupferman M, Koch W, Bell R, Saba N, Panwar A, Annino D, Wagner L, Ferris R, Burtness B. Reduced Aspiration Rates for 50 Gy Postoperative Radiation in HPV-Associated Oropharynx Cancer in E3311: A Trial of the ECOG-ACRIN Cancer Research Group. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: s27-s28. DOI: 10.1016/j.ijrobp.2022.07.380.Peer-Reviewed Original ResearchTransoral surgerySite cliniciansCentral reviewPostoperative radiotherapyOropharyngeal cancerExact testECOG-ACRIN Cancer Research GroupMD Anderson Cancer CenterIntermediate-risk HPVPrimary transoral surgeryBarium swallow studyCancer Research GroupAnderson Cancer CenterAspiration rateFisher's exact testExcellent disease controlOropharynx cancerPostoperative radiationRisk HPVRandomized armTrials databasesCancer CenterFunctional outcomeMBS studiesSwallow study
2020
A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311
Ferris RL, Flamand Y, Holsinger FC, Weinstein GS, Quon H, Mehra R, Garcia JJ, Hinni ML, Gross ND, Sturgis EM, Duvvuri U, Méndez E, Ridge JA, Magnuson JS, Higgins KA, Patel MR, Smith RB, Karakla DW, Kupferman ME, Malone JP, Judson BL, Richmon J, Boyle JO, Bayon R, O'Malley BW, Ozer E, Thomas GR, Koch WM, Bell RB, Saba NF, Li S, Sigurdson ER, Burtness B. A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311. Oral Oncology 2020, 110: 104797. PMID: 32679405, PMCID: PMC7771718, DOI: 10.1016/j.oraloncology.2020.104797.Peer-Reviewed Original ResearchConceptsOropharyngeal cancerTransoral surgeryOropharyngeal bleedingPositive marginsTransoral resectionGrade III/IVSurgical oncology trialsPost-operative therapySurgical quality assuranceSurgical pathology reportsFinal pathologic marginsMulti-institutional dataPathologic marginsBleeding rateClinical trialsPathology reportsLower incidenceOngoing quality assuranceOncology trialsSurgical expertiseMeticulous evaluationSurgeon expertiseTransoral headPatientsSurgery
2019
Impact of contralateral lymph nodal involvement and extranodal extension on survival of surgically managed HPV-positive oropharyngeal cancer staged with the AJCC eighth edition
Miccio JA, Verma V, Kelly J, Kann BH, An Y, Park HS, Eskander A, Burtness B, Husain Z. Impact of contralateral lymph nodal involvement and extranodal extension on survival of surgically managed HPV-positive oropharyngeal cancer staged with the AJCC eighth edition. Oral Oncology 2019, 99: 104447. PMID: 31630059, DOI: 10.1016/j.oraloncology.2019.104447.Peer-Reviewed Original ResearchConceptsOropharyngeal squamous cell carcinomaExtranodal extensionLymphovascular invasionKaplan-Meier overall survival analysisContralateral lymph node involvementHPV-positive oropharyngeal cancerFuture staging systemsNational Cancer DatabaseLymph node involvementLymph nodal involvementSquamous cell carcinomaAJCC eighth editionOverall survival analysisPathologic nodalInferior OSNodal involvementNode involvementWorse OSClinical stagingPrognostic factorsOropharyngeal cancerPositive marginsPrognostic importanceCell carcinomaCox regressionRole of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion
Adelstein DJ, Ismaila N, Ku JA, Burtness B, Swiecicki PL, Mell L, Beitler JJ, Gross N, Jones CU, Kaufman M, Le QT, Semrad TJ, Siu LL, Ridge JA. Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion. Journal Of Clinical Oncology 2019, 37: jco.19.00441. PMID: 31021656, DOI: 10.1200/jco.19.00441.Peer-Reviewed Original ResearchConceptsProvisional clinical opinionASCO's provisional clinical opinionsTreatment deintensificationOropharyngeal cancerClinical opinionClinical trialsGood prognosis subsetPractice-changing dataTransoral surgical techniquesAmerican Joint CommitteeCancer (AJCC) staging systemEarly-stage diseaseCurrent treatment standardsCurrent treatment approachesCurrent eighth editionLong-term toxicityBetter treatment resultsLate toxicitySystemic treatmentStaging systemIntensity-modulated radiation therapy (IMRT) planningSurgical techniqueTherapeutic decisionsAmeliorate toxicityASCO's membershipOA01 Impact of Contralateral Lymph Node Involvement on Survival of Surgically-Managed HPV-Positive Oropharyngeal Cancer Staged with the AJCC Eighth Edition
Miccio J, Kelly J, Kann B, An Y, Park H, Verma V, Mehra S, Judson B, Burtness B, Husain Z. OA01 Impact of Contralateral Lymph Node Involvement on Survival of Surgically-Managed HPV-Positive Oropharyngeal Cancer Staged with the AJCC Eighth Edition. International Journal Of Radiation Oncology • Biology • Physics 2019, 103: e1. DOI: 10.1016/s0360-3016(19)30402-x.Peer-Reviewed Original Research
2018
Treatment Delays in Primarily Resected Oropharyngeal Squamous Cell Carcinoma: National Benchmarks and Survival Associations
Morse E, Judson B, Husain Z, Burtness B, Yarbrough WG, Sasaki C, Cheraghlou S, Mehra S. Treatment Delays in Primarily Resected Oropharyngeal Squamous Cell Carcinoma: National Benchmarks and Survival Associations. Otolaryngology 2018, 159: 987-997. PMID: 30060700, DOI: 10.1177/0194599818779052.Peer-Reviewed Original ResearchHPV-positive patientsRadiation treatment durationTotal treatment packageOverall survivalTreatment initiationTreatment durationEnd intervalOropharyngeal cancerTreatment delayTreatment packageOropharyngeal squamous cell carcinomaCox proportional hazards regressionMultivariable logistic regression analysisRadiation treatmentRetrospective cross-sectional analysisNational Cancer DatabaseProportional hazards regressionSquamous cell carcinomaDuration of diagnosisLogistic regression analysisNational benchmarksCross-sectional analysisMedian durationOverall cohortHazards regressionNational treatment times in oropharyngeal cancer treated with primary radiation or chemoradiation
Morse E, Judson B, Husain Z, Burtness B, Yarbrough W, Sasaki C, Cheraghlou S, Mehra S. National treatment times in oropharyngeal cancer treated with primary radiation or chemoradiation. Oral Oncology 2018, 82: 122-130. PMID: 29909886, DOI: 10.1016/j.oraloncology.2018.02.010.Peer-Reviewed Original ResearchConceptsRadiation treatment durationHuman papilloma virus-positive tumorsVirus-positive tumorsOverall survivalOropharyngeal cancerTreatment durationTreatment endMedian durationTreatment initiationTreatment delayHuman papilloma virus-associated tumorsHuman papilloma virus-negative tumorsEnd intervalOropharyngeal squamous cell carcinomaCox proportional hazards regressionNational Cancer DatabaseProportional hazards regressionSquamous cell carcinomaVirus-associated tumorsVirus-negative tumorsMultivariable logisticHazards regressionCell carcinomaHuman papillomaCancer Database
2017
NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.
Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD. NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. Journal Of The National Comprehensive Cancer Network 2017, 15: 761-770. PMID: 28596256, DOI: 10.6004/jnccn.2017.0101.Peer-Reviewed Original ResearchConceptsNeck cancerHuman papillomavirus-associated oropharyngeal cancerNCCN Clinical Practice GuidelinesNCCN Guidelines InsightsClinical practice guidelinesTreatment of patientsImmunotherapy agentsOccult primaryOropharyngeal cancerMost recent recommendationsTreatment recommendationsMaxillary sinusPractice guidelinesOral cavityCancerRecent recommendationsSalivary glandsHeadPatientsSinusRecommendationsRecurrentNeckOncologyPharynx
2016
Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting
Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le Q, Raben D, Strome SE, Lynn J, Malik S. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer 2016, 123: 1259-1271. PMID: 27906454, PMCID: PMC5705038, DOI: 10.1002/cncr.30449.Peer-Reviewed Original ResearchConceptsNational Cancer InstituteClinical trialsCancer InstituteRecurrent/metastatic HNSCCNational Clinical Trials NetworkNeck squamous cell carcinomaClinical trial conceptsRandomized phase 2Use of immunotherapySquamous cell carcinomaStandard of careDifferent patient populationsClinical Trials NetworkClinical trial designNew immunotherapeutic targetsPhase 2Key immune componentsDifferent immunotherapiesOncologic communityImmunotherapeutic trialsMetastatic HNSCCOropharyngeal cancerImmunotherapeutic targetCell carcinomaPatient population
2014
Oropharyngeal squamous cell carcinoma treatment
Marur S, Burtness B. Oropharyngeal squamous cell carcinoma treatment. Current Opinion In Oncology 2014, 26: 252-258. PMID: 24626127, PMCID: PMC5813288, DOI: 10.1097/cco.0000000000000072.Peer-Reviewed Original ResearchConceptsHigh-risk human papilloma virusOropharyngeal squamous cell carcinomaHPV-unrelated cancersSquamous cell carcinomaNodal stageCell carcinomaTumor stageSquamous cell carcinoma treatmentHPV-unrelated tumorsAdvanced nodal stageRisk of deathCurrent treatment paradigmsHuman papilloma virusParaffin-embedded tissue blocksImportant causative factorAdvanced nodalDistant diseaseHPV statusCurative therapyFavorable prognosisOropharyngeal cancerRetrospective studyPapilloma virusTreatment paradigmRisk groups
2010
Nonsurgical management of oropharyngeal, laryngeal, and hypopharyngeal cancer: The Fox Chase Cancer Center experience
Andrews G, Lango M, Cohen R, Feigenberg S, Burtness B, Mehra R, Ahmed S, Nicolaou N, Gaughan J, Ridge JA. Nonsurgical management of oropharyngeal, laryngeal, and hypopharyngeal cancer: The Fox Chase Cancer Center experience. Head & Neck 2010, 33: 1433-1440. PMID: 21928415, DOI: 10.1002/hed.21615.Peer-Reviewed Original ResearchMeSH KeywordsCancer Care FacilitiesCarcinoma, Squamous CellChemoradiotherapy, AdjuvantCohort StudiesDisease-Free SurvivalFemaleHumansHypopharyngeal NeoplasmsLaryngeal NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalOropharyngeal NeoplasmsProportional Hazards ModelsRadiotherapy, ConformalRadiotherapy, Intensity-ModulatedRetrospective StudiesSalvage TherapySmokingConceptsSurvival of patientsNumber of patientsOropharyngeal cancerHypopharyngeal cancerT classificationLaryngeal cancerFox Chase Cancer Center experienceRetrospective single-institution cohort studyMultivariate analysisSingle-institution cohort studyRecurrent oropharyngeal cancerCancer Center experienceRecurrence-free survivalSubset of patientsLaryngeal cancer patientsDisease-related deathEarly T classificationHypopharyngeal cancer treatmentChemotherapy useCurative intentLocoregional controlCohort studyCurrent smokersOverall survivalSalvage surgery